Evidence map›Paper›PMID 38965371›Full record

ArticleLeukemia2024

Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction.

Anthony V Moorman, Amir Enshaei, Daniel Murdy, Melvin Joy, Judith M Boer, Monique L den Boer, Rob Pieters, Valerie de Haas, Martin A Horstmann, Gabriele Escherich and 6 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Revisiting novel genomic classifiers in the era of immunotherapy for pediatric B-ALL.Hematology. American Society of Hematology. Education Program · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Anthony V MoormanLeukaemia Research Cytogenetics Group, Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK. anthony.moorman@newcastle.ac.uk.ORCID 0000-0002-9781-6107
Amir EnshaeiLeukaemia Research Cytogenetics Group, Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0002-7464-0743
Daniel MurdyLeukaemia Research Cytogenetics Group, Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Melvin JoyLeukaemia Research Cytogenetics Group, Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0001-9323-994X
Judith M BoerPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0003-4848-7789
Monique L den BoerPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0002-5795-2921
Rob PietersPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0003-2997-3570
Valerie de HaasPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0003-0339-6816
Martin A HorstmannResearch Institute Children's Cancer Center Hamburg, Hamburg and Department of Pediatric Oncology and Hematology, University Medical Center, 20246, Hamburg, Germany.ORCID 0000-0001-8559-8862
Gabriele EscherichResearch Institute Children's Cancer Center Hamburg, Hamburg and Department of Pediatric Oncology and Hematology, University Medical Center, 20246, Hamburg, Germany.
Bertil JohanssonDepartment of Laboratory Medicine, Division of Clinical Genetics, Lund University, Lund, Sweden.ORCID 0000-0001-8829-4813
Hanne V MarquartDepartment of Clinical Immunology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0001-9740-6522
Kjeld SchmiegelowDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-0829-4993
Jeremy HancockBristol Genetics Laboratory, North Bristol NHS Trust, Bristol, UK.
John MoppettDepartment of Haematology, Bristol Children's Hospital, Bristol, UK.ORCID 0000-0003-1844-3531
Mats HeymanAstrid Lindgren Children's Hospital, Karolinska University Hospital and Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-7637-1949

Funding

Cancer Research UK (CRUK) CRCBPA-Jul21\100004
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Neoplasm, ResidualPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAdolescentAdultChildFemaleHumansInduction ChemotherapyMalePrognosis

Identifiers

PMID38965371
PMCPMC11347368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.